Richard Keith Bestwick

This inventor holds 36 USPTO granted patents and 31 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Oligonucleotide Therapeutics. Top assignees: Sarepta Therapeutics, Inc., Agritope, Inc., Epitope Limited. Active years: 1994-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Keith Bestwick. Retrieved from https://idiyas.com/inventor/richard-keith-bestwick

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 31)

% Patents Active = 94.4

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 19)

Average Co-Inventor Count = 2.5

ph-index = 11

Forward Citations = 531(Granted Patents)

Location History:

Portland, OR (US) (1994 - 2009)
Corvallis, OR (US) (2008 - 2022)
Cambridge, MA (US) (2020 - 2023)
Bend, OR (US) (2021 - 2024)

Company Filing History:

17 out of 127

Sarepta Therapeutics, Inc.

Orasure Technologies, Inc.

patents

5. 2 out of 11

Progeria Research Foundation, Inc.

patents

6. 2 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

7. 2 out of 2,027

University System of Maryland

Scripps Research Institute

patents

11. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...

Areas of Expertise:

Oligonucleotide Analogues

Exon Skipping

Muscular Dystrophy

Plant Genetic Transformation

Antisense Composition

Ethylene Biosynthesis

Transgenic Plants

Biological Control

Floral Preservatives

Antiviral Compounds

Virus Infection Assays

Promoter Methods

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11932851 - Exon skipping compositions for treating muscular dystrophy (2024-03-19),

2. 11802283 - Oligonucleotide analogues targeting human LMNA (2023-10-31),

3. 11491238 - Exon skipping oligomer conjugates for muscular dystrophy (2022-11-08),

4. 11384105 - Processes for preparing oligomers (2022-07-12),

5. 11236338 - Antisense-induced exon2 inclusion in acid alpha-glucosidase (2022-02-01),

6. 11071749 - Oligonucleotide analogues targeting human LMNA (2021-07-27),

7. 11015200 - Antisense-induced exon exclusion in myostatin (2021-05-25),

8. 10907154 - Exon skipping compositions for treating muscular dystrophy (2021-02-02),

9. 10875880 - Processes for preparing oligomers (2020-12-29),

10. 10822608 - Oligonucleotide analogues targeting human LMNA (2020-11-03),

11. 10758629 - Exon skipping oligomer conjugates for muscular dystrophy (2020-09-01),

12. 10076536 - Oligonucleotide analogues targeting human LMNA (2018-09-18),

13. 9682097 - Oligonucleotide analogues targeting human LMNA (2017-06-20),

14. 9217148 - Exon skipping compositions for treating muscular dystrophy (2015-12-22),

15. 9066967 - Oligonucleotide analogues targeting human LMNA (2015-06-30),

Dear valued reader,

Title: The Inventor Extraordinaire - Richard Keith Bestwick

Introduction:

Richard Keith Bestwick, a brilliant mind in the field of innovation, hails from Corvallis, OR in the United States. With an impressive portfolio of 17 patents, his contributions to the realm of technology are truly transformative.

Latest Patents:

Bestwick's latest patents showcase his expertise and focus on cutting-edge solutions. One of his recent inventions includes oligonucleotide analogues targeting human LMNA. These antisense oligonucleotides aim to reduce the expression of aberrantly spliced LMNA mRNA isoforms that encode progerin. Additionally, he has developed exon skipping oligomer conjugates for muscular dystrophy, demonstrating his commitment to pioneering medical advancements.

Career Highlights:

Bestwick's professional journey has been marked by collaborations with esteemed organizations. He has made significant contributions at Sarepta Therapeutics, Inc., where his innovative ideas have flourished. Moreover, his affiliation with the University of Maryland underscores his dedication to academic excellence and research-driven initiatives.

Collaborations:

Throughout his career, Bestwick has had the privilege of working alongside accomplished individuals such as Ryszard M Kole and Diane Elizabeth Frank. These collaborations have fueled creativity and propelled the development of groundbreaking inventions.

Conclusion:

In conclusion, Richard Keith Bestwick stands as a beacon of innovation, shaping the landscape of technology with his inventive spirit and unwavering dedication. His patents represent a legacy of excellence that continues to inspire future generations in the pursuit of scientific advancement.

Warm regards,

Diya from idiyas.com

Profile summary based on public USPTO records.